Can management of the components of metabolic syndrome modify the course of chronic kidney disease?

Metabolic syndrome (MetS), described for the first time by Reaven in 1988, refers to a set of conditions including central obesity, systemic hypertension, hyperglycemia, and dyslipidemia [1]. The criteria for MetS have changed since its original description. The concept of insulin resistance that le...

Full description

Saved in:
Bibliographic Details
Published inKidney research and clinical practice Vol. 39; no. 2; pp. 118 - 120
Main Authors Kim, Yaeni, Park, Cheol Whee
Format Journal Article
LanguageEnglish
Published Korean Society of Nephrology 01.06.2020
The Korean Society of Nephrology
대한신장학회
Subjects
내과학
Online AccessGet full text

Cover

More Information
Summary:Metabolic syndrome (MetS), described for the first time by Reaven in 1988, refers to a set of conditions including central obesity, systemic hypertension, hyperglycemia, and dyslipidemia [1]. The criteria for MetS have changed since its original description. The concept of insulin resistance that leads to subsequent chronic inflammation and endothelial dysfunction lies at its core [2]. KCI Citation Count: 4
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
Edited by Gheun-Ho Kim, Hanyang University, Seoul, Republic of Korea
ISSN:2211-9132
2211-9140
DOI:10.23876/j.krcp.20.066